Hatch Medical, LLC, a medical device incubator and technology brokerage firm, announces that it has recently entered into an agreement with Pursuit Vascular, Inc. to broker its patent-pending catheter infection reduction technology.
Pursuit Vascular, Inc. has developed a unique disposable device intended to significantly reduce costly and potentially deadly catheter infections. The ClearGuard device is easily inserted into any brand of hemodialysis catheter and through its proprietary technology, is engineered to kill infectious organisms between dialysis treatments.
Steve Hvozda, principal at Hatch Medical, states, We are very pleased to be working so closely with Pursuit Vascular on this project, and believe the ClearGuard technology addresses a significant unmet clinical need that has been echoed by numerous clinicians over the years. Although a variety of techniques have been used to control infection between dialysis treatments, none has been proven to be universally effective, or accepted.
Robert Ziebol, Pursuit Vasculars president and CEO, comments, Pursuit Vascular expects ClearGuard to reduce catheter infections by over 75 percent potentially saving tens of thousands of lives, and saving our healthcare system hundreds of millions of dollars in reduced hospitalizations every year. We are pleased to have the expertise of Hatch Medical on our side and look forward to working with Hatch to secure a partner committed to bringing this novel device to market.
This ClearGuard technology is now available and may be licensed or acquired by interested third parties through an exclusive agreement with Hatch Medical.
For additional information, visit: